Skip to content

US · PMVP · BIOTECHNOLOGY

PMV Pharmaceuticals, Inc. (PMVP) intrinsic value and stock valuation

$0.88as of 2026-11-21 · Mkt cap 62.4M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

PMV Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values PMVP with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PMVP’s statements →

PMV Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Princeton, NJ 08540 pmvpharma.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-77.74M
20182025
Free cash flow
-$-73.61M
20182025
Total equity
$104.7M-21.8% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-86.21M-$-85.45M-$-80.13M-$-77.04M-$-58.29M
Net income-$-77.74M-$-58.71M-$-68.96M-$-73.32M-$-57.85M
EPSd-$-1.48M-$-1.14M-$-1.44M-$-1.61M-$-1.28M
Operating cash flow-$-73.58M-$-51.28M-$-55.66M-$-63.76M-$-46.57M
Capital expenditure-$-30K-$-660K-$-960K-$-7.98M-$-1.35M
Free cash flow-$-73.61M-$-51.94M-$-56.62M-$-71.74M-$-47.92M
Total assets$116.6M$191.3M$252.2M$270.3M$331.6M
Total debt$840K$1.19M$13.3M$14M$11.2M
Net debt-$-37.15M-$-39.69M-$-24.42M-$-94.32M-$-161.27M
Total equity$104.7M$176.1M$225.7M$246M$308.6M
Cash and short-term investments$112.9M$169.5M$203.1M$241.1M$297.2M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$1.14M$1.26M$650K$1.28M
Gross profit$0.00-$-1.14M-$-1.26M-$-650K-$-1.28M
Research and development expenses$69.9M$57.4M$54.6M$51.7M$36.2M
Selling, general and administrative expenses$16.3M$26.9M$24.3M$24.7M$20.8M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$86.2M$84.3M$78.9M$76.4M$57M
Cost and expenses$86.2M$85.5M$80.1M$77M$58.3M
Interest income$6.34M$10.7M$11.2M$3.63M$450K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$130K$1.14M$1.26M$650K$1.28M
Ebitda-$-79.78M-$-73.67M-$-67.7M-$-72.68M-$-56.54M
Operating income-$-86.21M-$-85.45M-$-80.13M-$-77.04M-$-58.29M
Total other income/expenses, net$6.29M$10.6M$11.2M$3.71M$470K
Income before tax-$-79.91M-$-74.81M-$-68.96M-$-73.33M-$-57.82M
Income tax expense-$-2.17M-$-16.1M$0.00-$-10K$20K
Net income-$-77.74M-$-58.71M-$-68.96M-$-73.32M-$-57.85M
Weighted average shares outstanding$52.5M$51.6M$48M$45.6M$45.1M
Weighted average diluted shares outstanding$52.5M$51.6M$48M$45.6M$45.1M
Balance sheet
20252024202320222021
Cash and short-term investments$112.9M$169.5M$203.1M$241.1M$297.2M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$115.2M$175.7M$207.4M$247M$301.3M
Property, plant and equipment, net$1.04M$1.55M$19.1M$20.5M$13.2M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$13.8M$25.5M$2.5M$16.9M
Total non-current assets$1.33M$15.6M$44.7M$23.3M$30.3M
Total assets$116.6M$191.3M$252.2M$270.3M$331.6M
Accounts payable$3.15M$6.58M$3.24M$3M$3.19M
Short-term debt$400K$350K$850K$530K$400K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$11.4M$14.4M$14M$10.8M$12.2M
Long-term debt$430K$840K$12.4M$13.5M$10.8M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$430K$840K$12.4M$13.5M$10.8M
Capital lease obligations$400K$840K$13.3M$14M$11.2M
Total liabilities$11.9M$15.2M$26.5M$24.3M$23M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-446.45M-$-368.71M-$-310M-$-241.04M-$-167.73M
Accumulated other comprehensive income (loss)$80K$140K$220K-$-450K-$-80K
Total equity$104.7M$176.1M$225.7M$246M$308.6M
Total investments$75M$142.4M$190.9M$135.3M$141.6M
Total debt$840K$1.19M$13.3M$14M$11.2M
Net debt-$-37.15M-$-39.69M-$-24.42M-$-94.32M-$-161.27M
Cash flow statement
20252024202320222021
Net income-$-77.74M-$-58.71M-$-68.96M-$-73.32M-$-57.85M
Depreciation and amortization$130K$1.14M$1.26M$650K$1.28M
Stock-based compensation$5.92M$8.87M$12.4M$10.2M$5.34M
Change in working capital$910K-$-1.59M$5.43M-$-570K$4.12M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-3.42M$3.34M$230K-$-390K$190K
Net cash provided by operating activities-$-73.58M-$-51.28M-$-55.66M-$-63.76M-$-46.57M
Investments in property, plant and equipment-$-30K-$-660K-$-960K-$-7.98M-$-1.35M
Acquisitions, net$30K$250K$0.00$0.00$0.00
Net cash used for investing activities$70.2M$53.4M-$-50.55M-$-1.37M-$-143.58M
Common stock issued$510K$310K$35.1M$960K$2.02M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$510K$310K$35.6M$960K$2.02M
Net change in cash-$-2.89M$2.35M-$-70.59M-$-64.17M-$-188.13M
Cash at end of period$38M$40.9M$38.5M$109.1M$173.3M
Operating cash flow-$-73.58M-$-51.28M-$-55.66M-$-63.76M-$-46.57M
Capital expenditure-$-30K-$-660K-$-960K-$-7.98M-$-1.35M
Free cash flow-$-73.61M-$-51.94M-$-56.62M-$-71.74M-$-47.92M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About PMV Pharmaceuticals, Inc.

        PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.

        CEO
        David H. Mack
        Employees
        54
        Beta
        1.33

        Explore

        Frequently asked questions

        What is the intrinsic value of PMV Pharmaceuticals, Inc. (PMVP)?

        InvestorsCraft does not currently publish an intrinsic value for PMVP. How the IC value is calculated.

        Is PMVP undervalued?

        InvestorsCraft does not publish an undervaluation signal for PMVP at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.